Artiva Biotherapeutics, Inc. Cash and Restricted Cash
Artiva Biotherapeutics, Inc. (ARTV) had Cash and Restricted Cash of $301.92 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $301.92M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $21.42M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $27.16M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $25.97M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $301.92M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $21.42M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $27.16M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $25.97M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $28.93M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $30.86M 10-Q · filed 2026-05-08 |
| 2024-12-31 | $40.49M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $56.14M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $34.51M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $48.46M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $53.76M 10-K · filed 2026-03-10 |
| 2023-09-30 | $66.14M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $53.95M 10-Q · filed 2024-08-29 |
| 2022-12-31 | $102.78M 10-K · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |